Ovid Therapeutics (OVID) Competitors $0.29 0.00 (-0.21%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$0.29 +0.00 (+0.21%) As of 09:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OVID vs. VIRI, OCX, ARTV, JMAC, ANIX, XCUR, SNTI, BDTX, PLRX, and VIGLShould you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Virios Therapeutics (VIRI), OncoCyte (OCX), Artiva Biotherapeutics (ARTV), Maxpro Capital Acquisition (JMAC), Anixa Biosciences (ANIX), Exicure (XCUR), Senti Biosciences (SNTI), Black Diamond Therapeutics (BDTX), Pliant Therapeutics (PLRX), and Vigil Neuroscience (VIGL). These companies are all part of the "pharmaceutical products" industry. Ovid Therapeutics vs. Virios Therapeutics OncoCyte Artiva Biotherapeutics Maxpro Capital Acquisition Anixa Biosciences Exicure Senti Biosciences Black Diamond Therapeutics Pliant Therapeutics Vigil Neuroscience Virios Therapeutics (NASDAQ:VIRI) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, community ranking, risk, profitability, dividends, media sentiment and valuation. Do analysts prefer VIRI or OVID? Virios Therapeutics currently has a consensus price target of $3.00, indicating a potential upside of 0.33%. Ovid Therapeutics has a consensus price target of $3.03, indicating a potential upside of 959.12%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Ovid Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in VIRI or OVID? Ovid Therapeutics received 354 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 70.97% of users gave Ovid Therapeutics an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformVirios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% Ovid TherapeuticsOutperform Votes35770.97% Underperform Votes14629.03% Which has more volatility & risk, VIRI or OVID? Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Does the media favor VIRI or OVID? In the previous week, Ovid Therapeutics had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 1 mentions for Ovid Therapeutics and 0 mentions for Virios Therapeutics. Ovid Therapeutics' average media sentiment score of 0.93 beat Virios Therapeutics' score of 0.00 indicating that Ovid Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Virios Therapeutics Neutral Ovid Therapeutics Positive Is VIRI or OVID more profitable? Virios Therapeutics has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -5,142.56%. Ovid Therapeutics' return on equity of -39.24% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Ovid Therapeutics -5,142.56%-39.24%-26.19% Do insiders and institutionals hold more shares of VIRI or OVID? 9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 13.3% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable earnings & valuation, VIRI or OVID? Virios Therapeutics has higher earnings, but lower revenue than Ovid Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-11.07Ovid Therapeutics$566K35.96-$52.34M-$0.38-0.75 SummaryOvid Therapeutics beats Virios Therapeutics on 14 of the 18 factors compared between the two stocks. Remove Ads Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVID vs. The Competition Export to ExcelMetricOvid TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.36M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.616.8121.7017.82Price / Sales35.96225.96377.7294.61Price / CashN/A65.6738.1534.64Price / Book0.235.866.464.00Net Income-$52.34M$141.86M$3.20B$247.23M7 Day Performance2.73%4.38%2.77%1.44%1 Month Performance-33.99%-12.76%-8.60%-6.26%1 Year Performance-90.97%-11.13%10.40%0.59% Ovid Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVIDOvid Therapeutics4.4308 of 5 stars$0.29-0.2%$3.03+959.1%-91.1%$20.36M$566,000.00-0.6160Gap DownVIRIVirios TherapeuticsN/A$4.25+1.7%$3.00-29.4%+534.8%$81.85MN/A-15.745Gap UpOCXOncoCyte2.4045 of 5 stars$2.84+2.5%$4.56+60.7%+16.2%$81.22M$1.88M-0.65120Gap UpARTVArtiva BiotherapeuticsN/A$3.31+35.7%$20.40+516.3%N/A$80.64M$251,000.000.0081Gap UpHigh Trading VolumeJMACMaxpro Capital AcquisitionN/A$6.00-10.6%N/A-45.0%$80.57MN/A0.002,021Gap UpANIXAnixa Biosciences2.9044 of 5 stars$2.49-1.6%$9.00+261.4%-9.8%$80.17M$210,000.00-6.385Gap UpXCURExicure1.784 of 5 stars$12.48-4.0%N/A+1,823.4%$78.82M$500,000.00-6.0350Short Interest ↓News CoverageGap DownSNTISenti Biosciences2.7608 of 5 stars$2.97+1.7%$10.00+236.7%+21.8%$77.23M$2.56M-0.194Short Interest ↑BDTXBlack Diamond Therapeutics3.1369 of 5 stars$1.36-2.9%$14.60+973.5%-72.8%$77.06MN/A-1.0290Short Interest ↑Gap DownPLRXPliant Therapeutics4.2236 of 5 stars$1.25-6.7%$13.31+965.0%-89.2%$76.55M$1.58M-0.3790Positive NewsVIGLVigil Neuroscience3.1967 of 5 stars$1.54-1.3%$16.25+955.2%-50.9%$75.65MN/A-0.7540Positive News Remove Ads Related Companies and Tools Related Companies VIRI Alternatives OCX Alternatives ARTV Alternatives JMAC Alternatives ANIX Alternatives XCUR Alternatives SNTI Alternatives BDTX Alternatives PLRX Alternatives VIGL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OVID) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OVID Stock Free OVID Stock Alerts